The total number of approved indications reached 8, and Hengrui Medicine Carrelizumab added two new indications

The new indications approved this time are: combined paclitaxel and carboplatin for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer, combined with paclitaxel and cisplatin for unresectable locally advanced / recurrent or metastatic esophagus First-line treatment for patients with squamous cell carcinoma

Consolidate its position in the field of lung cancer immunotherapy

Achieve full coverage of NSCLC squamous cell carcinoma and non-squamous cell carcinoma

In non-small cell lung cancer (NSCLC) patients, squamous NSCLC patients account for about 30%.

The approval of carrelizumab for the first-line treatment of squamous NSCLC is based on the excellent results of the CameL-sq study, a multi-center, randomized controlled, double-blind, phase III clinical study

The results of the study showed that, as assessed by the independent review committee, the median progression-free survival (mPFS) of patients in the carrelizumab combined chemotherapy group reached 8.

It can be observed in both the CameL-sq study in the field of squamous NSCLC and the CameL study in the field of non-squamous NSCLC that the combination of carrelizumab and chemotherapy on the main efficacy indicators ORR, PFS and OS has shown a more potent effect The characteristics of the immunotherapy mechanism of action

The success of CameL-sq and CameL research and the approval of related indications indicate that Carrelizumab has completed the full coverage of NSCLC squamous cell carcinoma and non-squamous cell carcinoma in the field of NSCLC, further consolidating its position in the field of lung cancer immunotherapy

Completion of the second-line treatment of esophageal squamous cell carcinoma

Will bring survival benefits to more patients

Esophageal cancer is one of the most common malignant tumors in China.

The approval of Carrelizumab for the first-line treatment of esophageal squamous cell carcinoma is based on the results of a multi-center, randomized, double-blind, phase III clinical study-ESCORT-1st study

Based on excellent data, the ESCORT-1st study was awarded the 2021 ASCO conference oral report, and was also published online in full text by the international authoritative journal and one of the four major medical journals, the Journal of the American Medical Association (JAMA), becoming the world’s first and only A clinical study of immunotherapy for esophageal cancer that appeared in JAMA magazine

In 2019, a landmark study in the field of esophageal cancer immunotherapy -ESCORT research achieved breakthrough success, and carrelizumab was approved as a second-line treatment indication for esophageal squamous cell carcinoma

Carrelizumab continues to expand its indications

Leading the number of approved indications and tumor coverage

Since its launch in May 2019, the exploration of carrelizumab in different tumor species has blossomed, and good news have been reported frequently

As a domestic PD-1 monoclonal antibody, the success of carrelizumab is of greater significance to Chinese patients: its research data comes from Chinese patients and is suitable for guiding clinical practice in China; its multiple indications are included in the country The medical insurance catalogue continuously improves the accessibility and affordability of immunotherapy

Hengrui Pharmaceuticals, as an innovative national pharmaceutical company, has been committed to "technology-based, creating a healthy life for mankind" for many years, practicing innovation and internationalization, a two-wheel drive development strategy, and is committed to solving unmet clinical needs.